Novartis NVS announced that the Committee for Medicinal Products for Human Use (“CHMP”) of the European Medicines Agency (EMA ...

Basel, October 27, 2024 – Novartis today presented 12-month data from the Phase III APPEAR-C3G study at American Society of Nephrology (ASN) Kidney Week 2024 showing that patients with C3 ...

Oct 28 (Reuters) - Swiss pharmaceutical giant Novartis (NOVN.S), opens new tab will pay Monte Rosa Therapeutics (GLUE.O), opens new tab $150 million upfront payment for a global license to develop ...

Oct 16 (Reuters) - Novartis (NOVN.S), opens new tab has lost a bid to keep a generic version of its top-selling heart failure drug Entresto off the U.S. market by blocking regulators from ...

Novartis (NVS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Steve Scala from ...

The previous update I wrote on Novartis was the Q2 earnings preview and I want to note that while my estimates on some of the key growth products were off, the general direction of my prediction ...

Novartis is a pharmaceutical powerhouse with ... According to Marazzi, while the organization has garnered attention for innovative products that can reduce mortality and morbidity, the persistent ...

Novartis is another leading drugmaker with an extensive lineup of approved products. Several of the company's medicines are doing much of the heavy lifting in driving its top line in the right ...

Narasimhan is confident that Novartis will achieve its goal of increasing sales by an average of 5% annually by 2028.

Novartis AG ( (NVS) ) has realeased its Q3 earnings. Here is a breakdown of the information Novartis AG presented to its investors. Novartis AG ...

Novartis NVS announced that the Committee for Medicinal Products for Human Use (“CHMP”) of the European Medicines Agency (EMA) recommended granting approval to the breast cancer drug Kisqali ...